Apo-quetiapine Xr - May Exceed The Established Acceptable Intake Limit For N-nitroso-desalkyl-quetiapine (nnap).
APO-QUETIAPINE XR tablets are being recalled in Canada because they may contain higher levels of a potentially harmful impurity called N-nitroso-desalkyl-quetiapine (NNAP) than what is considered safe. This is a Class I recall, meaning the product poses a serious health risk. The recall affects all APO-QUETIAPINE XR distributed across Canada.
- Product
- APO-QUETIAPINE XR
- Reason
- Product quality
- Classification
- Class I
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2025-01-31
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/9ea63206-d5c4-456c-9681-9cc709e18bbc